SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $12.00.
Several equities analysts have recently weighed in on SABS shares. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a report on Monday, June 15th. Chardan Capital raised their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Barclays began coverage on shares of SAB Biotherapeutics in a research note on Wednesday. They issued an “overweight” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th.
Get Our Latest Analysis on SABS
Institutional Inflows and Outflows
SAB Biotherapeutics Price Performance
Shares of NASDAQ SABS opened at $3.80 on Monday. The firm’s 50-day moving average price is $3.70 and its 200-day moving average price is $3.85. SAB Biotherapeutics has a 1-year low of $1.67 and a 1-year high of $6.60. The firm has a market capitalization of $290.55 million, a P/E ratio of -1.80 and a beta of 0.54. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01.
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Equities research analysts anticipate that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.
The company’s lead programs are directed primarily at infectious diseases.
Read More
- Five stocks we like better than SAB Biotherapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
